Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21216118 | 0.88 | KDM1A (0.46) | KDM1AATMPRMT5PTPRBPTPN11 | |
| SCHEMBL20535903 | 0.87 | KDM1A (0.34) | KDM1AOPRK1 | |
| SCHEMBL20535067 | 0.86 | KDM4E (0.37) | OPRK1 | |
| SCHEMBL21216287 | 0.86 | JAK2 (0.34) | GPR119PTPRBPTPN11 | |
| SCHEMBL21216112 | 0.84 | JAK2 (0.44) | KDM1AATMPRMT5PTPRBPTPN11 | |
| SCHEMBL21216231 | 0.84 | JAK2 (0.44) | KDM1AATMPRMT5PTPRBPTPN11 | |
| SCHEMBL20535916 | 0.84 | NR1D1 (0.35) | OPRK1 | |
| SCHEMBL21216318 | 0.82 | KDM1A (0.42) | KDM1AATMPDE8BCHEK2OPRD1 | |
| SCHEMBL21216115 | 0.80 | SIGMAR1 (0.42) | — | |
| SCHEMBL21216116 | 0.75 | ATM (0.40) | KDM1AATMPDE8BCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | SILICON VALLEY BANK | 2021-02-18 | — | — | US | disclosed |
| EP-3743433-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | Evonetix Ltd (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019145713-A9 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2020-08-06 | — | — | WO | disclosed |
| WO-2019145713-A9 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2020-08-06 | — | — | WO | disclosed |
| EP-3609866-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | Evonetix Ltd (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2019145713-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019145713-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | EVONETIX LTD (GB) | 2019-08-01 | — | — | WO | disclosed |
| WO-2018189546-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | EVONETIX LTD (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199681-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | KDM1A 4095/4885ATM 3172/4885PRMT5 2760/4885 |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | KDM1A 1656/4885ATM 3283/4885PRMT5 2600/4885 |
| US-20210047361-A1 | OLIGONUCLEOTIDE AND NUCLEIC ACID SYNTHESIS | POLN, POLI, ADAR | KDM1A 4095/4885ATM 3172/4885PRMT5 2760/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | KDM1A 1656/4885ATM 3283/4885PRMT5 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.